Noxa and cancer therapy

Biochemical analyses have characterized the BH3-only protein family member Noxa as a “sensitizer” with weak pro-apoptotic activity. Investigations into cancer cell responses to chemotherapeutic agents have identified Noxa as a pivotal factor mediating the cytotoxic effect of a plethora of anticancer treatments independent of its own pro-apoptotic activity. Accumulating evidence now suggests that tumor cells exert a number of strategies to counteract Noxa function by exploiting diverse cellular regulatory circuits that normally govern Noxa expression during cellular stress responses. Here, we summarize data concerning the role of Noxa in cancer chemosensitivity and highlight the potential of this enigmatic BH3-only protein family member in current and novel anticancer therapies.

[1]  P. Hersey,et al.  Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. , 2008, Cancer research.

[2]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Kofler,et al.  Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells , 2009, Apoptosis.

[4]  R. Bataille,et al.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.

[5]  A. Roulston,et al.  Programming cancer cells for high expression levels of Mcl1 , 2013, EMBO reports.

[6]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[7]  P. Hersey,et al.  Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737 , 2011, Clinical Cancer Research.

[8]  R. Youle,et al.  The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division , 2007, The Journal of cell biology.

[9]  R. Jemmerson,et al.  The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. , 2010, Molecules and Cells.

[10]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[11]  G M Cohen,et al.  NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1 , 2012, Cell Death and Differentiation.

[12]  M. Butterworth,et al.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells , 2010, Haematologica.

[13]  R. Craig,et al.  MCLI , a gene expressed in programmed myeloid cell differentiation , has sequence similarity to BCL 2 , 2005 .

[14]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[15]  S. Akira,et al.  Integral role of Noxa in p53-mediated apoptotic response. , 2003, Genes & development.

[16]  A. Eastman,et al.  Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737 , 2013, Molecular Cancer Therapeutics.

[17]  G. Melino,et al.  E1A Activates Transcription of p73 and Noxa to Induce Apoptosis* , 2005, Journal of Biological Chemistry.

[18]  A. Kraft,et al.  Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. , 2012, Cancer research.

[19]  R. Craig.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis , 2002, Leukemia.

[20]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[21]  A. Kater,et al.  Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.

[22]  Xiaoling Li,et al.  Dual role of SIRT1 in UVB-induced skin tumorigenesis , 2014, Oncogene.

[23]  Simeon Santourlidis,et al.  Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. , 2013, Cellular signalling.

[24]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[25]  A. Strasser,et al.  Pro-apoptotic BH3-only Bcl-2 family members in vertebrate model organisms suitable for genetic experimentation , 2002, Cell Death and Differentiation.

[26]  Xu Luo,et al.  Perturbation of the Bcl-2 Network and an Induced Noxa/Bcl-xL Interaction Trigger Mitochondrial Dysfunction after DNA Damage* , 2010, The Journal of Biological Chemistry.

[27]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[28]  P. D. Davies,et al.  Thapsigargin-coated intraocular lenses inhibit human lens cell growth , 1997, Nature Medicine.

[29]  K. Mori,et al.  Activation of mammalian unfolded protein response is compatible with the quality control system operating in the endoplasmic reticulum. , 2004, Molecular biology of the cell.

[30]  L. Zhang,et al.  Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways , 2011, Cell Death and Differentiation.

[31]  Qiuyan Wang,et al.  Inhibition of p97-dependent Protein Degradation by Eeyarestatin I* , 2008, Journal of Biological Chemistry.

[32]  S. Lowe,et al.  Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. , 2005, Cancer research.

[33]  I. Pollack,et al.  ABT-737 Synergizes with Bortezomib to Induce Apoptosis, Mediated by Bid Cleavage, Bax Activation, and Mitochondrial Dysfunction in an Akt-Dependent Context in Malignant Human Glioma Cell Lines , 2012, Journal of Pharmacology and Experimental Therapeutics.

[34]  D. Ginsberg,et al.  Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis* , 2004, Journal of Biological Chemistry.

[35]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[36]  G. Lenz,et al.  Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. , 2011, Genes & development.

[37]  G. Cohen,et al.  Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells , 2008 .

[38]  P. Juin,et al.  pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737 , 2013, Cell Death and Differentiation.

[39]  C. Scott,et al.  Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. , 2011, Cancer research.

[40]  F. Sinicrope,et al.  Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 , 2008, Clinical Cancer Research.

[41]  P. Hersey,et al.  Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. , 2009, Neoplasia.

[42]  G. Descamps,et al.  The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction , 2011, British Journal of Cancer.

[43]  M. Saha,et al.  PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa , 2013, Molecular Cancer Therapeutics.

[44]  P. Agostinis,et al.  Pro-apoptotic signaling induced by photo-oxidative ER stress is amplified by Noxa, not Bim. , 2013, Biochemical and biophysical research communications.

[45]  K. Suk,et al.  BH3-only Protein Noxa Is a Mediator of Hypoxic Cell Death Induced by Hypoxia-inducible Factor 1α , 2004, The Journal of experimental medicine.

[46]  M. Hendrix,et al.  Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.

[47]  Michael J. Schell,et al.  Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. , 2013, Cell reports.

[48]  Seamus J. Martin,et al.  Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. , 2011, Molecular cell.

[49]  Qiuyan Wang,et al.  ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells , 2009, Proceedings of the National Academy of Sciences.

[50]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[51]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[52]  W. Wilson,et al.  Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma , 2011, Clinical Cancer Research.

[53]  O. Coutelle,et al.  The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. , 2010, Cancer research.

[54]  C. Billard,et al.  Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia , 2012, Leukemia.

[55]  M. Hendrix,et al.  p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. , 2004, Molecular cancer therapeutics.

[56]  G. Basso,et al.  Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa , 2013, Oncotarget.

[57]  G. Cohen,et al.  Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa , 2007, Leukemia.

[58]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[59]  K Brinkmann,et al.  Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? , 2014, Cell Death and Disease.

[60]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[61]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[62]  J. Litz,et al.  Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 , 2009, Molecular Cancer Therapeutics.

[63]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[64]  W. Lu,et al.  Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells , 2012, PloS one.

[65]  N. Kato,et al.  Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13-acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line , 1990, Journal of virology.

[66]  E. May,et al.  Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB , 2007, Oncogene.

[67]  W. Xie,et al.  Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. , 2007, Neoplasia.

[68]  G. Ott,et al.  Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma , 2014, Cell Death and Disease.

[69]  E. Campo,et al.  Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters , 2011, Clinical Cancer Research.

[70]  Laurent Poulain,et al.  Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis , 2013, Apoptosis.

[71]  R. Flockhart,et al.  Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells* , 2009, The Journal of Biological Chemistry.

[72]  W. Paul,et al.  Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. , 2013, Cancer cell.

[73]  M. Verheij,et al.  Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B , 2012, Cell Death and Disease.

[74]  J. Wang,et al.  ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia , 2011, Oncogene.

[75]  C. Keller,et al.  Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma , 2011, Journal of Neuro-Oncology.

[76]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[77]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[78]  C. Scott,et al.  Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. , 2013, Blood.

[79]  D. Saur,et al.  HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.

[80]  S. Varambally,et al.  Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition , 2007, Proceedings of the National Academy of Sciences.

[81]  Z. Giricz,et al.  NOXA contributes to the sensitivity of PERK‐deficient cells to ER stress , 2012, FEBS letters.

[82]  BCL-2 inhibitor yields high response in CLL and SLL. , 2014, Cancer discovery.